PEG-IFN riba in order of $20,000 for a course
telaprevir and presumably boceprevir in order of $50,000 for a course
the latter have probably set the benchmark for future pricings
HIV is the very interesting area as the viral loads are lower, and the theoretical 10-fold reduction of BIT225 from ape studies is more significant. It remains to be seen what the effect on macrophages has on disease course.
victrelis approved in austr, page-6
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
